Edition:
United States

Profile: Aeterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

2.12USD
21 Sep 2017
Change (% chg)

$-0.03 (-1.44%)
Prev Close
$2.15
Open
$2.15
Day's High
$2.20
Day's Low
$2.01
Volume
391,553
Avg. Vol
2,063,746
52-wk High
$5.59
52-wk Low
$0.78

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Company Address

Aeterna Zentaris Inc

315 Sigma Dr Ste 302D
SUMMERVILLE   SC   29486-7790
P: +1843.9003223
F: +1418.9489191

Company Web Links